Key points are not available for this paper at this time.
In this case, a woman with refractory diffuse large-B-cell lymphoma had a CNS recurrence that responded completely to anti-CD19 CAR T-cell therapy. After biopsy of a subsequent skin recurrence, the lesions cleared in association with an expansion of the CAR T cells in the blood.
Abramson et al. (Wed,) studied this question.